Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

NCT02193282 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02193282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02193282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 11, 2015
Completion date
February 3, 2027
Enrollment
390 (actual)
Sites
1,407

Conditions

As the registry lists them; a condition with its own page is linked.

lung non-squamous non-small cell carcinoma, stage ib lung non-small cell carcinoma ajcc v7, stage ii lung non-small cell cancer ajcc v7, stage iia lung non-small cell carcinoma ajcc v7, stage iib lung non-small cell carcinoma ajcc v7, stage iiia lung non-small cell cancer ajcc v7